JnJ to submit applications for at least 10 new drugs by 2023

This is part of the healthcare conglomerate’s plan to deliver above-market growth through 2023 at its Janssen unit, JnJ said.
New Delhi: Johnson & Johnson said on Wednesday it expected to file marketing applications for at least 10 new drugs between 2019 to 2023, to strengthen its pharmaceuticals unit which has been a major growth driver.
This is part of the healthcare conglomerate’s plan to deliver above-market growth through 2023 at its Janssen unit, it said. The plan comes ahead of J&J’s business review, scheduled later on Wednesday.
Also Read: JnJ baby shampoo free from carcinogenic Formaldehyde; says Gujarat FDCA
The company said it would discuss four medicines that are new to J&J’s pipeline of drugs at its review as well as therapeutic areas such as gene therapy and RNA therapeutics.
Also Read: JnJ baby shampoo on attack; gets BANNED in Uttar Pradesh
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd